NCT04310137

Brief Summary

This study is designed to evaluate if how people are told to return to walking after a skin injury affects whether or not they develop new (recurrence) skin breakdown on their feet. The people in this study will have diabetes and have a recently closed foot ulcer. About half will be specifically told how to return to walking and the other half will be told to return to walking slowly. How people naturally return to walking will also be established.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 19, 2020

Completed
27 days until next milestone

First Posted

Study publicly available on registry

March 17, 2020

Completed
1.1 years until next milestone

Study Start

First participant enrolled

May 1, 2021

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

October 25, 2021

Status Verified

October 1, 2021

Enrollment Period

2.6 years

First QC Date

February 19, 2020

Last Update Submit

October 15, 2021

Conditions

Keywords

Diabetesre-loadingulcer recurrence

Outcome Measures

Primary Outcomes (3)

  • Incidence of Ulcer Recurrence

    Assessment of incidence of any plantarr ulcer recurrence.

    Over up to 18 months of follow-up.

  • Change in walking behavior (steps)

    Actual assessment of change in walking behavior will be assessed by number of steps.

    Assessed initially and every 6 months for 1 week for up to 18 months.

  • Change in walking behavior (step timing)

    Actual assessment of change in walking behavior will be assessed by the timing of steps (how many steps in a given timeframe).

    Assessed initially and every 6 months for 1 week for up to 18 months.

Secondary Outcomes (4)

  • Exercise component of Summary of Diabetes Self-Care Activities Scale

    Assessed initially and every 6 months for up to 18 months

  • Bio-thesiometer

    Assessed initially and every 6 months for up to 18 months

  • Body Mass Index (BMI) and disease risk

    Assessed initially and every 6 months for up to 18 months

  • Waist circumference

    Assessed initially and every 6 months for up to 18 months

Study Arms (2)

Therapist-Directed Re-loading

EXPERIMENTAL

Participants in this arm will be instructed to increase their activity by walking 10% more steps per day than the steps recorded in the most recent activity monitoring (i.e. StepWatch) measurement (e.g. 10% more than the initial monitoring values and 10% more than the second monitoring values once they are completed).

Behavioral: Therapist-Directed Re-loading

Self-Directed Re-loading

NO INTERVENTION

Participants in this arm will be instructed to slowly increase their walking.

Interventions

Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.

Therapist-Directed Re-loading

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • With or without peripheral neuropathy
  • Able to safely exercise
  • Have a recently closed plantar ulceration

You may not qualify if:

  • Presence of an open plantar ulceration
  • Presence of an untreated infection
  • Presence of osteomyelitis or gangrene

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Piedmont Healthcare

Atlanta, Georgia, 30309, United States

RECRUITING

MeSH Terms

Conditions

Diabetic FootDiabetes Mellitus

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsEndocrine System DiseasesDiabetic NeuropathiesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Deborah M. Wendland

    Mercer University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Deborah M. Wendland, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The outcome assessor will be unaware of in which group the participant was randomized.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomized Controlled Trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 19, 2020

First Posted

March 17, 2020

Study Start

May 1, 2021

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

October 25, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will share

De-identified step data will be made available through a repository upon conclusion of the study and its dissemination.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will be available following the study conclusion and its dissemination (6 months after publication).
Access Criteria
This information will be shared with researchers for meta-analyses through the data repository.

Locations